FLDM CLASS ACTION DEADLINE: Bernstein Liebhard Reminds Investors of the Lead Plaintiff Deadline in a Securities Fraud Class Action Against Fluidigm Corporation

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that purchased or acquired the securities of Fluidigm Corporation (“Fluidigm” or the “Company”) (NASDAQ: FLDM) between February 7, 2019, and November 5, 2019(the “Class Period”). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934.

If you purchased Fluidigm securities, and/or would like to discuss your legal rights and options please visit FLDM Shareholder Class Action Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected].

The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) that Fluidigm was experiencing longer sales cycles; (2) that, as a result, Fluidigm’s revenue was reasonably likely to decline; and (3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On November 5, 2019, after the market closed, Fluidigm reported that third quarter 2019 revenue declined 8.5% year-over-year primarily due to mass cytometry instrument sales. On this news, the Company’s share price fell $2.60, or 51% to close at $2.51 per share on November 6, 2019.

If you wish to serve as lead plaintiff, you must move the Court no later than November 20, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

If you purchased Fluidigmsecurities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/fluidigmcorporation-fldm-shareholder-class-action-lawsuit-stock-fraud-312/apply/   contact Matthew E. Guarnero toll free at (877) 779-1414 or [email protected].

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2020 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin.  Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information
Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
[email protected]



Almaden Discovers Veins Cropping Out In the Southeast Alteration Zone of Ixtaca Property

VANCOUVER, British Columbia, Nov. 18, 2020 (GLOBE NEWSWIRE) — Almaden Minerals Ltd. (“Almaden” or “the Company”; TSX: AMM; NYSE American: AAU) is pleased to announce that several areas of possible high-level epithermal veining have been identified cropping out within the Southeast (“SE”) Alteration Zone of the Ixtaca Project.

This area is a focus of the Company’s current exploration program as discussed in the Company’s news release of October 27th, 2020. The discovery of veining within several outcrops within the SE Alteration Zone is further evidence of the areas’ potential for hosting additional zones of epithermal mineralization. The newly identified zones of veining may represent higher levels of a potential underlying epithermal system. These new veins have been sampled by an independent qualified person, as defined by NI 43-101, whose samples have been submitted for analysis at ALS Global in Zacatecas, Mexico (a fully accredited and independent laboratory).

The Company is currently planning additional prospecting and mapping in this area. A map showing the location of the samples recently collected within the SE Alteration Zone is included below.

About the
SE Alteration Zone

The Ixtaca deposit occurs in both the overlying volcanic rocks and the older underlying carbonate sedimentary rocks. The bulk of the gold and silver bearing epithermal veins comprising the Ixtaca deposit are hosted by the underlying sedimentary rocks, while the overlying volcanic unit is typically mineralized at its base and clay altered above. This alteration appears to extend to the southeast of the Ixtaca deposit area where a topographic high exposes a section of the overlying volcanic rocks with significant clay alteration in an area measuring about 1.5 kilometre (km) east-west by 1 km north-south, which is referred to as the SE Alteration Zone, which is centred approximately 1km south east of the Ixtaca deposit.

The SE Alteration Zone comprises white argillic (clay-altered) volcanics and, most interestingly, clusters of anomalies identified from a hyperspectral survey that include the spectral signatures of important epithermal alteration minerals such as kaolinite, alunite and buddingtonite. The Company believes that there is significant potential for the discovery of a new zone of epithermal mineralization in the sedimentary rocks beneath the SE Alteration Zone and possibly at other similar anomalies in the area.

Any mineralization found within the SE Alteration Zone would represent a new discovery as this area lies well outside of the current Ixtaca deposit resource area, which was the focus of a Feasibility Study (results of which were announced by the Company in December, 2018), and 2019 environmental permit application. A report titled “Ixtaca Gold-Silver Project, Puebla State, Mexico NI 43-101 Technical Report on the Feasibility Study”, which was prepared in accordance with NI 43-101, is available under the Company’s profile on SEDAR and on the Company’s website.

Exploration Opportunities

The Ixtaca deposit is one of several exploration targets on the Company’s mineral claims, which cover an area of high-level epithermal clay alteration. The project area is partially covered by volcanic ash deposits which mask underlying alteration, potential vein zones and associated soil responses. In areas devoid of this covering ash soil sampling has defined several distinct zones of elevated gold and silver values and trace elements typically associated with epithermal vein systems. The Ixtaca zone is one of the largest areas of gold/silver soil response but it is also one of the areas with the least ash cover on the project.

Management believes that the other altered and geochemically anomalous areas could represent additional zones of underlying quartz-carbonate epithermal veining like the Ixtaca zone. The potential quantity and grade of these exploration targets is conceptual in nature. There has been insufficient exploration and/or study to define these exploration targets as a Mineral Resource. It is uncertain if additional exploration will result in these exploration targets being delineated as a Mineral Resource. The potential quantity and grade of these exploration targets has not been used in this Study.

Andrew J. Turner, B.Sc., P.Geol. of APEX Geoscience Ltd., and a Qualified Person as defined by National Instrument 43-101 (“NI 43-101”), has reviewed and approved the scientific and technical contents of this news release which relate to the outcropping veins in the SE Alteration Zone. Morgan J. Poliquin, Ph.D., P. Eng., President and CEO of Almaden, and a Qualified Person as defined by National Instrument 43-101 (“NI 43-101”), has reviewed and approved all other scientific and technical contents of this news release.

About Almaden

Almaden Minerals Ltd. owns 100% of the Ixtaca project in Puebla State, Mexico, subject to a 2.0% NSR royalty held by Almadex Minerals Ltd. The Ixtaca Gold-Silver Deposit was discovered by Almaden in 2010.

On Behalf of the Board of Directors,





J. Duane


Poliquin”


J. Duane Poliquin, P. Eng
Chairman
Almaden Minerals Ltd.


Forward Looking Statements

Certain of the statements and information in this news release constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian provincial securities laws. All statements, other than statements of historical fact, are forward-looking statements or information. Forward-looking statements or information in this news releas
e relate to, among other things:
the outcome or nature of any exploration programs at Ixtaca, and the ability of the Company to comply with COVID-19 related health protocols
.

These forward-looking statements and information reflect the Company’s current views with respect to future events and are necessarily based upon a number of assumptions, including assumptions in respect of both Almaden’s and the applicable Mexican Authorities’ legal positions, that, while considered reasonable by the Company, are inherently subject to significant legal, regulatory, business, operational and economic uncertainties and contingencies, and such uncertainty generally increases with longer-term forecasts and outlook. These assumptions include: stability and predictability in Mexico’s mineral tenure, mining, environmental and agrarian laws and regulations, as well as their application and judicial decisions thereon; continued respect for the rule of law in Mexico; prices for gold, silver and base metals remaining as estimated; currency exchange rates remaining as estimated; availability of funds; capital, decommissioning and reclamation estimates; mineral reserve and resource estimates; prices for energy inputs, labour, materials, supplies and services (including transportation); no labour-related disruptions; all necessary permits, licenses and regulatory approvals being received in a timely manner; the ability to secure and maintain title
and ownership to properties and the surface rights necessary for
exploration and
operations; community support in the Ixtaca Project
,
and the ability of the Company to comply with environmental, health and safety laws. The foregoing list of assumptions is not exhaustive.

The Company cautions the reader that forward-looking statements and information involve known and unknown risks, uncertainties and other factors that may cause actual results and developments to differ materially from those expressed or implied by such forward-looking statements or information contained in this news release. Such risks and other factors include, among others, risks related to: political risk in Mexico; crime and violence in Mexico; corruption; environmental risks, including environmental matters under Mexican laws and regulations; impact of environmental impact assessment requirements on the Company’s planned exploration and development activities on the Ixtaca Project; certainty of mineral title and the outcome of litigation; community relations; governmental regulations and the ability to obtain necessary licences and permits; risks related to mineral properties being subject to prior unregistered agreements, transfers or claims and other defects in title; changes in mining, environmental or agrarian laws and regulations and changes in the application of standards pursuant to existing laws and regulations which may increase costs of doing business and restrict operations; as well as those factors discussed the section entitled “Risk Factors” in Almaden’s Annual Information Form and Almaden’s latest Form 20-F on file with the United States Securities and Exchange Commission in Washington, D.C. Although the Company has attempted to identify important factors that could affect the Company and may cause actual actions, events or results to differ materially from those described in forward-looking statements or information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that our forward-looking statements or information will prove to be accurate. Accordingly, readers should not place undue reliance on forward-looking statements or information. Except as required by law, the Company does not assume any obligation to release publicly any revisions to on forward-looking statements or information contained in this news release to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact Information:

Almaden Minerals Ltd.
Tel. 604.689.7644
Email: [email protected]
http://www.almadenminerals.com/

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2ca4d979-b61e-4760-92ac-500ead354f0b



Nuance Announces Fourth Quarter and Fiscal Year 2020 Results

– Delivered Revenue and EPS at high end of guidance range

– Continued strength in Dragon Medical One and emerging cloud-based Healthcare offerings

– Announced divestiture of medical transcription and EHR Go-Live services

– Provided FY’21 guidance and updating mid-term outlook

PR Newswire

BURLINGTON, Mass., Nov. 18, 2020 /PRNewswire/ — Nuance Communications, Inc. (NASDAQ: NUAN) today announced financial results for its fourth quarter and fiscal year ended September 30, 2020:

  • GAAP revenue of $352.9 million and GAAP earnings per diluted share of $(0.08).
  • Non-GAAP revenue of $352.9 million and non-GAAP earnings per diluted share of $0.18.

“We are very pleased with the strong end to our fiscal year, as we delivered revenue and EPS at the high end of our guidance range,” said Mark Benjamin, Chief Executive Officer at Nuance. “We continued to execute on our strategic initiatives, accelerating our cloud transition in Healthcare and focusing on our AI-first approach in Enterprise. In Healthcare, we drove solid growth in our cloud offerings, ending the year at $386 million in cloud-based ARR, up 29% for the full year. In particular, we benefited from strong performance in Dragon Medical Cloud, which grew 38% compared to 2019, as well as growth in our PowerScribe One and CDE One offerings, as we continue to transition our customer base to the cloud. Enterprise revenue increased 4% compared to 2019, marking our fifth consecutive year of organic growth. This growth was driven by strength in our Intelligent Engagement offerings.”

Mr. Benjamin concluded, “In a separate release today, as part of our ongoing effort to align our portfolio with key strategic growth areas, we announced the planned sale of our medical transcription and electronic health record (EHR) Go-Live services to Assured Healthcare Partners and Aeries Technology Group. With this sale, we will reach an important milestone in our journey towards a more focused strategy of advancing our Conversational AI, natural language understanding and ambient clinical intelligence solutions. This crucial step in our portfolio rationalization efforts places Nuance in a strong position to achieve levels of organic growth not seen in many years, and I look forward to continuing on this path in the quarters to come.”

Q4 2020 Performance Summary

Q4 2020 results for continuing operations include:

  • Revenue of $352.9 million, compared to $387.6 million in the same period last year.
  • Non-GAAP revenue of $352.9 million, compared to $387.8 million in the same period last year.
  • GAAP operating income of $12.9 million, compared to $30.8 million in the same period last year.
  • Non-GAAP operating income of $76.3 million, compared to $94.1 million in the same period last year.
  • GAAP operating margin of 3.7%, compared to 7.9% in the same period last year.
  • Non-GAAP operating margin of 21.6%, compared to 24.3% in the same period last year.
  • GAAP net loss of $22.8 million, compared to a net income of $3.0 million in the same period last year.
  • Non-GAAP net income of $54.2 million, compared to $65.9 million in the same period last year.
  • GAAP EPS of $(0.08), compared to $0.01 in the same period last year.
  • Non-GAAP EPS of $0.18, compared to $0.23 in the same period last year.
  • Operating cash flows from continuing operations was $80.9 million, compared to $79.3 million in the same period last year.

Capital Allocation

We remain committed to our balanced capital allocation approach. While we did not engage in any share buyback or debt retirement activity during the fourth quarter, during the fiscal year we repurchased $169 million of common stock and retired $470 million of debt principal value, all of which took place in the first half of the year. We remain confident in the strength of our balance sheet and our solid liquidity position, ending the quarter with a cash and marketable securities balance of $372 million, slightly above our target minimum cash balance range.

For a complete discussion of Nuance’s results and business outlook, including our updated guidance, please see the Company’s Prepared Remarks document available at http://www.nuance.com/earnings-results/. We will also be providing an update to our mid-term outlook on our earnings call today (details below).

Please refer to the “Discussion of Non-GAAP Financial Measures,” and “GAAP to Non-GAAP Reconciliations,” included elsewhere in this release, for more information regarding the Company’s use of non-GAAP financial measures.

Conference Call and Prepared Remarks

Nuance will host a conference call today at 5:00 p.m. ET. To participate, please access the live webcast here, or by dialing 1-888-317-6003 (US and Canada) or 1-412-317-6061 (international) and referencing code 5887867.

Nuance will provide a copy of Prepared Remarks in combination with its press release. These remarks are offered to provide shareholders and analysts additional detail for analyzing the results. The remarks are available at http://investors.nuance.com/ and will not be read on the call.

About Nuance Communications, Inc.

Nuance Communications (NASDAQ: NUAN) is a technology pioneer with market leadership in conversational AI and ambient intelligence. A full-service partner trusted by 90 percent of US hospitals and 85 percent of the Fortune 100 companies worldwide, Nuance creates intuitive solutions that amplify people’s ability to help others.

Trademark reference: Nuance and the Nuance logo are registered trademarks or trademarks of Nuance Communications, Inc. or its affiliates in the United States and/or other countries. All other trademarks referenced herein are the property of their respective owners.

Safe Harbor and Forward-Looking Statements

Statements in this document regarding future performance and our management’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” “intends” or “estimates” or similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements, including but not limited to: the impact of the COVID-19 pandemic, the effects of competition, including pricing pressure, and changing business models in the markets and industries in which we operate; fluctuations in demand for our existing and future products; changes to economic, political, and regulatory conditions in the United States and internationally; our ability to attract and retain key personnel; our ability to control and successfully manage our expenses and cash position; cybersecurity and data privacy incidents or breaches, and related remediation and investigation; our ability to comply with applicable domestic and international laws and policies; fluctuating currency rates; possible quality issues in our products and technologies; our ability to realize anticipated synergies from acquired businesses, to cut stranded costs related to divested businesses, and to capture the expected value from strategic transactions; and the other factors described in our most recent Form 10-K, Form 10-Q and other filings with the Securities and Exchange Commission. We disclaim any obligation to update any forward-looking statements as a result of developments occurring after the date of this document.

Discussion of Non-GAAP Financial Measures

We believe that providing non-GAAP (“Generally Accepted Accounting Principles”) information to investors, in addition to the GAAP presentation, allows investors to view the financial results in the way management views the operating results. We further believe that providing this information allows investors not only to better understand our financial performance, but more importantly, to evaluate the efficacy of the methodology and information used by management to evaluate and measure such performance. The non-GAAP information included in this press release should not be considered superior to, or a substitute for, financial statements prepared in accordance with GAAP.

We utilize a number of different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of the business, for making operating decisions and for forecasting and planning for future periods. Our annual financial plan is prepared both on a GAAP and non-GAAP basis, and the non-GAAP annual financial plan is approved by our board of directors. Continuous budgeting and forecasting for revenue and expenses are conducted on a consistent non-GAAP basis (in addition to GAAP) and actual results on a non-GAAP basis are assessed against the non-GAAP annual financial plan. The board of directors and management utilize these non-GAAP measures and results (in addition to the GAAP results) to determine our allocation of resources. In addition, and as a consequence of the importance of these measures in managing the business, we use non-GAAP measures and results in the evaluation process to establish management’s compensation. For example, our annual bonus program payments are based upon the achievement of consolidated non-GAAP revenue and consolidated non-GAAP earnings per share financial targets. We consider the use of non-GAAP revenue helpful in understanding the performance of our business, as it excludes the purchase accounting impact on acquired deferred revenue and other acquisition-related adjustments to revenue. We also consider the use of non-GAAP earnings per share helpful in assessing the organic performance of the continuing operations of our business. By organic performance we mean performance as if we had owned an acquired business in the same period a year ago. By constant currency organic performance, we mean performance excluding the effect of current foreign currency rate fluctuations. By continuing operations, we mean the ongoing results of the business excluding certain unplanned costs. While our management uses these non-GAAP financial measures as a tool to enhance their understanding of certain aspects of our financial performance, our management does not consider these measures to be a substitute for, or superior to, the information provided by GAAP financial statements.

Consistent with this approach, we believe that disclosing non-GAAP financial measures to the readers of our financial statements provides such readers with useful supplemental data that, while not a substitute for GAAP financial statements, allows for greater transparency in the review of our financial and operational performance. In assessing the overall health of the business during the three months ended September 30, 2020 and 2019, our management has either included or excluded items in seven general categories, each of which is described below.

Acquisition-related revenue and cost of revenue.

We provide supplementary non-GAAP financial measures of revenue that include revenue that we would have recognized but for the purchase accounting treatment of acquisition transactions. Non-GAAP revenue also includes revenue that we would have recognized had we not acquired intellectual property and other assets from the same customer. Because GAAP accounting requires the elimination of this revenue, GAAP results alone do not fully capture all of our economic activities. These non-GAAP adjustments are intended to reflect the full amount of such revenue. We include non-GAAP revenue and cost of revenue to allow for more complete comparisons to the financial results of historical operations, forward-looking guidance and the financial results of peer companies. We believe these adjustments are useful to management and investors as a measure of the ongoing performance of the business because, although we cannot be certain that customers will renew their contracts, we have historically experienced high renewal rates on maintenance and support agreements and other customer contracts. Additionally, although acquisition-related revenue adjustments are non-recurring with respect to past acquisitions, we generally will incur these adjustments in connection with any future acquisitions.

Restructuring and other costs, net.

Restructuring and other charges, net include restructuring expenses as well as other charges that are unusual in nature, are the result of unplanned events, and arise outside the ordinary course of our business. Restructuring expenses consist of employee severance costs, charges for the closure of excess facilities and other contract termination costs. Other charges include litigation contingency reserves, costs related to the transition agreement of our former CEO, asset impairment charges, expenses associated with the malware incident that occurred in the third quarter of fiscal year 2017 (the “2017 Malware Incident”) and gains or losses on the sale or disposition of certain non-strategic assets or product lines.

Acquisition-related costs, net.

In recent years, we have completed a number of acquisitions, which result in operating expenses, that would not otherwise have been incurred. We provide supplementary non-GAAP financial measures, which exclude certain transition, integration and other acquisition-related expense items resulting from acquisitions, to allow more accurate comparisons of the financial results to historical operations, forward looking guidance and the financial results of less acquisitive peer companies. We consider these types of costs and adjustments, to a great extent, to be unpredictable and dependent on a significant number of factors that are outside of our control. Furthermore, we do not consider these acquisition-related costs and adjustments to be related to the organic continuing operations of the acquired businesses and are generally not relevant to assessing or estimating the long-term performance of the acquired assets. In addition, the size, complexity and/or volume of past acquisitions, which often drives the magnitude of acquisition related costs, may not be indicative of the size, complexity and/or volume of future acquisitions. By excluding acquisition-related costs and adjustments from our non-GAAP measures, management is better able to evaluate our ability to utilize our existing assets and estimate the long-term value that acquired assets will generate for us. We believe that providing a supplemental non-GAAP measure, which excludes these items allows management and investors to consider the ongoing operations of the business both with, and without, such expenses.

These acquisition-related costs fall into the following categories: (i) transition and integration costs; (ii) professional service fees and expenses; and (iii) acquisition-related adjustments. Although these expenses are not recurring with respect to past acquisitions, we generally will incur these expenses in connection with any future acquisitions. These categories are further discussed as follows:

(i) 

Transition and integration costs. Transition and integration costs include retention payments, transitional employee costs, and earn-out payments treated as compensation expense, as well as the costs of integration-related activities, including services provided by third parties.

(ii) 

Professional service fees and expenses. Professional service fees and expenses include financial advisory, legal, accounting and other outside services incurred in connection with acquisition activities, and disputes and regulatory matters related to acquired entities.

(iii) 

Acquisition-related adjustments. Acquisition-related adjustments include adjustments to acquisition-related items that are required to be marked to fair value each reporting period, such as contingent consideration, and other items related to acquisitions for which the measurement period has ended, such as gains or losses on settlements of pre-acquisition contingencies.

Amortization of acquired intangible assets.

We exclude the amortization of acquired intangible assets from non-GAAP expense and income measures. These amounts are inconsistent in amount and frequency and are significantly impacted by the timing and size of acquisitions. Providing a supplemental measure which excludes these charges allows management and investors to evaluate results “as-if” the acquired intangible assets had been developed internally rather than acquired and, therefore, provides a supplemental measure of performance in which our acquired intellectual property is treated in a comparable manner to our internally developed intellectual property. Although we exclude amortization of acquired intangible assets from our non-GAAP expenses, we believe that it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Future acquisitions may result in the amortization of additional intangible assets.

Non-cash expenses.

We provide non-GAAP information relative to the following non-cash expenses: (i) stock-based compensation; and (ii) non-cash interest. These items are further discussed as follows:

(i)

Stock-based compensation. Because of varying valuation methodologies, subjective assumptions and the variety of award types, we believe that excluding stock-based compensation allows for more accurate comparisons of operating results to peer companies, as well as to times in our history when stock-based compensation was more or less significant as a portion of overall compensation than in the current period. We evaluate performance both with and without these measures because compensation expense related to stock-based compensation is typically non-cash and the options and restricted awards granted are influenced by the Company’s stock price and other factors such as volatility that are beyond our control. The expense related to stock-based awards is generally not controllable in the short-term and can vary significantly based on the timing, size and nature of awards granted. As such, we do not include such charges in operating plans. Stock-based compensation will continue in future periods.

(ii)

Non-cash interest. We exclude non-cash interest because we believe that excluding this expense provides senior management, as well as other users of the financial statements, with a valuable perspective on the cash-based performance and health of the business, including the current near-term projected liquidity. Non-cash interest expense will continue in future periods.

Other expenses.

We exclude certain other expenses that result from unplanned events outside the ordinary course of continuing operations, in order to measure operating performance and current and future liquidity both with and without these expenses. By providing this information, we believe management and the users of the financial statements are better able to understand the financial results of what we consider to be our organic, continuing operations. Included in these expenses are items such as restructuring charges, asset impairments and other charges (credits), net, and losses from extinguishing our convertible debt. Other items such as consulting and professional services fees related to assessing strategic alternatives and our transformation programs, implementation of the new revenue recognition standard (ASC 606), and expenses associated with the malware incident and remediation thereof are also excluded.

Non-GAAP Operating Income

Our non-GAAP operating income includes acquisition-related revenue adjustments but excludes non-GAAP expenses such as stock compensation, amortization of intangible assets, restructuring and other costs, net, acquisition-related costs, net, and certain other expenses that result from unplanned events outside the ordinary course of continuing operations.

Non-GAAP income tax provision.

Our non-GAAP income tax provision is determined based on our non-GAAP pre-tax income. The tax effect of each non-GAAP adjustment, if applicable, is computed based on the statutory tax rate of the jurisdiction to which the adjustment relates. Additionally, as our non-GAAP profitability is higher based on the non-GAAP adjustments, we adjust the GAAP tax provision to remove valuation allowances and related effects based on the higher level of reported non-GAAP profitability. We also exclude from our non-GAAP tax provision certain discrete tax items as they occur.

Contact Information

For Investors 
Michael Maguire 
Nuance Communications, Inc. 
Tel: 781-565-4855 
Email: [email protected]

For Press

Nancy Scott

Nuance Communications, Inc.
Tel: 781-565-4130
Email: [email protected]


Financial Tables Follow

 

Nuance Communications, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

Unaudited

Three Months Ended
September 30,

Twelve Months Ended
September 30,

2020

2019

2020

2019


Revenues:

Hosting and professional services

$      234,749

$     235,539

$    926,044

$    913,643

Product and licensing

52,626

86,394

296,127

338,693

Maintenance and support

65,556

65,642

256,728

268,935

Total revenues

352,931

387,575

1,478,899

1,521,271


Cost of revenues:

Hosting and professional services

129,362

142,160

518,145

551,419

Product and licensing

7,829

10,809

61,995

71,280

Maintenance and support

7,952

8,556

30,989

33,369

Amortization of intangible assets

8,132

6,810

27,810

27,416

Total cost of revenues

153,275

168,335

638,939

683,484

Gross profit

199,656

219,240

839,960

837,787


Operating expenses:

Research and development

56,535

52,935

226,234

192,633

Sales and marketing

71,477

73,647

273,324

274,031

General and administrative

41,998

43,481

156,353

172,638

Amortization of intangible assets

14,682

13,176

50,897

54,206

Acquisition-related costs, net

(721)

2,525

2,884

7,965

Restructuring and other charges, net

2,748

2,701

17,680

29,147

Total operating expenses

186,719

188,465

727,372

730,620

Income from operations

12,937

30,775

112,588

107,167

Other expenses, net

(22,646)

(27,794)

(102,558)

(107,260)

(Loss) income before income taxes

(9,709)

2,981

10,030

(93)

Provision (benefit) for income taxes

13,042

(24)

(18,752)

12,105

Net (loss) income from continuing operations

(22,751)

3,005

28,782

(12,198)

Net (loss) income from discontinued operations

(1,194)

105,124

(7,386)

226,008


Net (loss) income

$       (23,945)

$     108,129

$      21,396

$    213,810


Net (loss) income per common share – basic:

Continuing operations

$           (0.08)

$           0.01

$          0.10

$         (0.04)

Discontinued operations

0.37

(0.02)

0.79

Total net (loss) income per basic common share

$           (0.08)

$           0.38

$          0.08

$          0.75


Net (loss) income per common share – diluted:

Continuing operations

$           (0.08)

$           0.01

$          0.10

$         (0.04)

Discontinued operations

0.36

(0.03)

0.79

Total net (loss) income per diluted common share

$           (0.08)

$           0.37

$          0.07

$          0.75


Weighted average common shares outstanding:

Basic

282,556

285,754

282,644

286,347

Diluted

282,556

291,598

291,994

286,347

 

Nuance Communications, Inc.

Condensed Consolidated Balance Sheets

(in thousands)

September 30, 2020

September 30, 2019

Unaudited


ASSETS

Current assets:

Cash and cash equivalents

$                    301,233

$                    560,961

Marketable securities

71,114

186,555

Accounts receivable, net

200,576

240,673

Prepaid expenses and other current assets

163,062

175,166

Current assets of discontinued operations

91,858

Total current assets

735,985

1,255,213

Marketable securities

17,287

Land, building and equipment, net

143,428

121,203

Goodwill

2,133,712

2,127,896

Intangible assets, net

213,484

291,371

Right-of-use assets

110,276

Other assets

256,447

316,215

Long-term assets of discontinued operations

1,236,608

Total assets

$                 3,593,332

$                 5,365,793


LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Current portion of long-term debt

$                    432,209

$                 1,142,870

Contingent and deferred acquisition payments

4,224

17,470

Accounts payable

75,122

90,826

Accrued expenses and other current liabilities

213,264

249,570

Deferred revenue

261,323

214,223

Current liabilities of discontinued operations

130,117

Total current liabilities

986,142

1,845,076

Long-term debt

1,104,464

793,536

Deferred revenue, net of current portion

104,309

133,783

Deferred tax liability

70,116

54,216

Operating lease liabilities

107,621

Other liabilities

76,747

79,378

Long-term liabilities of discontinued operations

286,654

Total liabilities

2,449,399

3,192,643

Stockholders’ equity

1,143,933

2,173,150

Total liabilities and stockholders’ equity

$                 3,593,332

$                 5,365,793

 

Nuance Communications, Inc.

Consolidated Statements of Cash Flows

(in thousands)

Unaudited

Three Months Ended
September 30,

Twelve Months Ended
September 30,

2020

2019

2020

2019


Cash flows from operating activities:

Net (loss) income from continuing operations

$    (22,751)

$         3,005

$       28,782

$      (12,198)

Adjustments to reconcile net (loss) income to net cash
provided by operating activities:

Depreciation

9,782

10,300

37,772

47,417

Amortization

22,814

19,986

78,707

81,622

Stock-based compensation

35,264

34,779

133,294

119,255

Non-cash interest expense

12,171

12,477

49,440

49,488

Deferred tax provision (benefit)

15,689

(7,311)

(39,937)

(12,437)

Loss on extinguishment of debt

18,656

910

Other

(169)

5,113

2,736

4,462

Changes in operating assets and liabilities, excluding
effects of acquisitions:

Accounts receivable

15,811

(8,952)

42,075

3,366

Prepaid expenses and other assets

(12,289)

(6,303)

(7,259)

(21,063)

Accounts payable

7,695

3,853

(8,173)

12,122

Accrued expenses and other liabilities

686

24,568

(84,076)

27,415

Deferred revenue

(3,852)

(12,221)

15,854

4,227

Net cash provided by operating activities – continuing
operations

80,851

79,294

267,871

304,586

Net cash provided by (used in) operating activities –
discontinued operations

24,869

(13,307)

96,771

Net cash provided by operating activities

80,851

104,163

254,564

401,357


Cash flows from investing activities:

Capital expenditures

(15,747)

(11,942)

(61,297)

(44,185)

Proceeds from disposition of a business, net of
transaction fees

150

150

407,043

Purchases of marketable securities and other
investments

(22,029)

(92,793)

(180,005)

(349,125)

Proceeds from sales and maturities of marketable
securities and other investments

23,150

40,257

313,734

303,171

Payments for business and asset acquisitions, net of
cash acquired

(1,000)

(17,771)

(1,000)

(20,873)

Other

(227)

1,147

Net cash (used in) provided by investing activities

(15,703)

(82,249)

72,729

296,031


Cash flows from financing activities:

Repurchase and redemption of debt

(513,642)

(300,000)

Net distribution from Cerence upon the spin-off

139,090

Payments for repurchase of common stock

(6,003)

(169,217)

(126,938)

Proceeds from issuance of common stock from
employee stock plans

7,636

7,954

14,840

16,597

Proceeds from the revolving credit facility

230,000

Repayment of the revolving credit facility

(230,000)

Payments for taxes related to net share settlement of
equity awards

(14,088)

(6,866)

(54,056)

(49,428)

Proceeds from sale of noncontrolling interests in a
subsidiary

9,863

9,863

Other financing activities

(381)

(689)

(3,222)

(2,131)

Net cash (used in) provided by financing activities

(6,833)

4,259

(586,207)

(452,037)

Effects of exchange rate changes on cash and cash
equivalents

2,363

(1,589)

(814)

(353)

Net increase (decrease) in cash and cash equivalents

60,678

24,584

(259,728)

244,998

Cash and cash equivalents at beginning of period

240,555

536,377

560,961

315,963

Cash and cash equivalents at end of period

$   301,233

$     560,961

$     301,233

$      560,961

 

Nuance Communications, Inc.

Supplemental Financial Information

GAAP to Non-GAAP Reconciliations

(in thousands)

Unaudited

Three Months Ended
September 30,

Twelve Months Ended
September 30,

2020

2019

2020

2019


GAAP revenues

$      352,931

$       387,575

$    1,478,899

$     1,521,271

Acquisition-related revenue adjustments: hosting and
professional services

134

301

531

Acquisition-related revenue adjustments: product and
licensing

2

660

Acquisition-related revenue adjustments: maintenance
and support

83

345


Non-GAAP revenues

$      352,931

$       387,794

$    1,479,200

$     1,522,807


GAAP cost of revenues

$      153,275

$       168,335

$       638,939

$        683,484

Cost of revenues from amortization of intangible
assets

(8,132)

(6,810)

(27,810)

(27,416)

Cost of revenues adjustments: hosting and
professional services (1)

(6,637)

(8,001)

(24,887)

(26,647)

Cost of revenues adjustments: product and licensing
(1)

(127)

(262)

(510)

(855)

Cost of revenues adjustments: maintenance and
support (1)

(457)

(584)

(1,663)

(1,314)

Cost of revenues adjustments: other

96

(1)

(378)


Non-GAAP cost of revenues

$      137,922

$       152,774

$       584,068

$        626,874


GAAP gross profit

$      199,656

$       219,240

$       839,960

$        837,787

Gross profit adjustments

15,353

15,780

55,172

58,146


Non-GAAP gross profit

$      215,009

$       235,020

$       895,132

$        895,933


GAAP income from operations

$        12,937

$         30,775

$       112,588

$        107,167

Gross profit adjustments

15,353

15,780

55,172

58,146

Research and development (1)

8,796

6,940

34,902

22,508

Sales and marketing (1)

9,018

8,751

32,040

30,394

General and administrative (1)

10,229

10,241

39,292

37,537

Acquisition-related costs, net

(721)

2,525

2,884

7,965

Amortization of intangible assets

14,682

13,176

50,897

54,206

Restructuring and other charges, net

2,748

2,701

17,680

29,147

Other

3,291

3,243

3,939

15,883


Non-GAAP income from operations

$        76,333

$         94,132

$       349,394

$        362,953


GAAP (loss) income before income taxes

$         (9,709)

$           2,981

$         10,030

$               (93)

Gross profit adjustments

15,353

15,780

55,172

58,146

Research and development (1)

8,796

6,940

34,902

22,508

Sales and marketing (1)

9,018

8,751

32,040

30,394

General and administrative (1)

10,229

10,241

39,292

37,537

Acquisition-related costs, net

(721)

2,525

2,884

7,965

Amortization of intangible assets

14,682

13,176

50,897

54,206

Restructuring and other charges, net

2,748

2,701

17,680

29,147

Non-cash interest expense

12,171

12,477

49,440

49,488

Loss on extinguishment of debt

18,656

910

Other

3,186

7,860

1,949

19,156


Non-GAAP income before income taxes

$        65,753

$         83,432

$       312,942

$        309,364

 

Nuance Communications, Inc.

Supplemental Financial Information

GAAP to Non-GAAP Reconciliations, continued

(in thousands, except per share amounts)

Unaudited

Three Months Ended
September 30,

Twelve Months Ended
September 30,

2020

2019

2020

2019


GAAP provision (benefit) for income taxes

$      13,042

$           (24)

$    (18,752)

$      12,105

Income tax effect of non-GAAP adjustments

13,262

190,352

58,752

263,334

Removal of valuation allowance and other items

(9,865)

(193,925)

26,851

(220,532)

Removal of discrete items

(4,844)

21,091

2,718

22,002


Non-GAAP provision for income taxes

$      11,595

$     17,494

$     69,569

$      76,909


GAAP net (loss) income from continuing operations

$    (22,751)

$       3,005

$     28,782

$    (12,198)

Acquisition-related adjustment – revenues (2)

219

301

1,536

Acquisition-related costs, net

(721)

2,525

2,884

7,965

Cost of revenue from amortization of intangible assets

8,132

6,810

27,810

27,416

Amortization of intangible assets

14,682

13,176

50,897

54,206

Restructuring and other charges, net

2,748

2,701

17,680

29,147

Stock-based compensation (1)

35,264

34,779

133,294

119,255

Non-cash interest expense

12,171

12,477

49,440

49,488

Loss on extinguishment of debt

18,656

910

Adjustment to income tax expense

1,447

(17,518)

(88,321)

(64,804)

Other

3,186

7,764

1,950

19,534


Non-GAAP net income

$      54,158

$     65,938

$   243,373

$    232,455


Non-GAAP diluted net income per share

$          0.18

$         0.23

$         0.83

$          0.80


Diluted weighted average common shares
outstanding

303,689

291,598

291,994

290,125

 

Nuance Communications, Inc.

Supplemental Financial Information – GAAP to Non-GAAP Reconciliations, continued

(in thousands)

Unaudited

Three Months Ended
September 30,

Twelve Months Ended
September 30,

2020

2019

2020

2019


(1) Stock-based compensation

Cost of hosting and professional services

$     6,637

$     8,001

$     24,887

$     26,647

Cost of product and licensing

127

262

510

855

Cost of maintenance and support

457

584

1,663

1,314

Research and development

8,796

6,940

34,902

22,508

Sales and marketing

9,018

8,751

32,040

30,394

General and administrative

10,229

10,241

39,292

37,537

Total

$   35,264

$   34,779

$   133,294

$   119,255


(2) Acquisition-related revenue

Acquisition-related revenue adjustments

$            —

$        219

$          301

$       1,536

Total

$            —

$        219

$          301

$       1,536

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/nuance-announces-fourth-quarter-and-fiscal-year-2020-results-301176448.html

SOURCE Nuance Communications, Inc.

Stoke Therapeutics Announces Proposed Public Offering

Stoke Therapeutics Announces Proposed Public Offering

BEDFORD, Mass.–(BUSINESS WIRE)–
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to 2,500,000 shares of its common stock. In addition, Stoke intends to grant the underwriters a 30-day option to purchase up to an additional 375,000 shares of common stock. All of the shares of common stock are being offered by Stoke. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

J.P. Morgan Securities LLC, Cowen and Company, LLC, and Credit Suisse Securities (USA) LLC are acting as joint book-running managers in the offering. Canaccord Genuity LLC and Cantor Fitzgerald & Co. are acting as passive bookrunners in the offering.

Stoke intends to use the net proceeds from the proposed offering, together with its existing cash and cash equivalents, to fund research, clinical and process development and manufacturing of its product candidates, including late stage development of STK-001, clinical development of its next target for the treatment of Autosomal Dominant Optic Atrophy, developing additional product candidates, working capital, capital expenditures and other general corporate purposes.

The shares are being offered by Stoke pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (the “SEC”). A preliminary prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone: (866) 803-9204, or by emailing [email protected]; from Cowen and Company, LLC c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone: (833) 297-2926, or by emailing [email protected]; or from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, NC 27560, by telephone at (800) 221-1037, or by email at [email protected]. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Stoke, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK) is a biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements the Company makes regarding its intention to conduct an offering and sale of securities, the grant of the option to purchase additional shares, the ability to complete the offering and expected use of proceeds, Stoke’s plan to develop its precision medicine platform, anticipated preclinical and clinical development activities, potential benefits of Stoke’s product candidates and potential market opportunities for Stoke’s product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although Stoke believes that the expectations reflected in such forward-looking statements are reasonable, Stoke cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the impact of the COVID-19 pandemic on the Company’s business, clinical trial sites, supply chain and manufacturing facilities, market conditions, the satisfaction of customary closing conditions related to the proposed offering, as well as other risks and uncertainties described under the heading “Risk Factors” in documents Stoke files from time to time with the SEC. These forward-looking statements speak only as of the date hereof and Stoke specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.

Stoke Media & Investor Contact:

Dawn Kalmar

Vice President, Head of Corporate Affairs

[email protected]

781-303-8302

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Biotechnology Health Genetics Pharmaceutical Clinical Trials

MEDIA:

Logo
Logo

Adamas to Present at Upcoming Piper Sandler Conference

EMERYVILLE, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) — Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held December 1-3, 2020.

A replay of the pre-recorded fireside chat will be available beginning November 23, 2020 in the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. The replay will be available for 30 days.

About Adamas Pharmaceuticals, Inc.

At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

Contact

Media:

Sarah Mathieson
Vice President, Corporate Communications
510-450-3528
[email protected]

Investors:

Peter Vozzo
Managing Director, Westwicke
443-213-0505
[email protected]



Nuance Announces Sale of HIM Transcription and EHR Go-Live Services Businesses to Accelerate Growth as Conversational AI Market Leader

Newly formed DeliverHealth in collaboration with Nuance will provide expanded offerings of value-added services to improve health system operations, revenue integrity, and patient care

PR Newswire

BURLINGTON, Mass., Nov. 18, 2020 /PRNewswire/ — Nuance Communications, Inc. (NASDAQ: NUAN) today announced the planned sale of the Health Information Management (HIM) Transcription business and the Electronic Health Record (EHR) Go-Live Services business to a new independent company, DeliverHealth Solutions LLC (DeliverHealth), formed by Assured Healthcare Partners® (AHP®) in partnership with Aeries Technology Group (Aeries). The HIM Transcription business includes both Nuance Transcription Services (NTS) and the eScription technology platform. The transaction is expected to be completed in early 2021. Nuance will be a minority shareholder of DeliverHealth and will continue to provide its technology to the company.

The sale provides mutual strategic and commercial benefits for customers, Nuance, and DeliverHealth by:

  • Giving existing customers continued service quality, newly expanded offerings, and enhancements from DeliverHealth in close collaboration with Nuance
  • Enabling Nuance to focus its innovation and market resources as a pure-play conversational AI market leader while providing continuity of EHR Go-Live Services and HIM Transcription businesses to existing and new customers via DeliverHealth
  • Empowering DeliverHealth to leverage a leading position in healthcare professional and technology-enabled services, expand global market share, advance growth plans for the EHR Go-Live and Optimization Services, and provide enhanced HIM technology and services to a worldwide market in partnership with Nuance

Nuance’s growth and market leadership in healthcare are driven by the accelerating adoption and development of its core cloud-based AI solutions, including the Nuance® Dragon® Ambient eXperience™ (Nuance DAX™) ambient clinical intelligence (ACI) solution, Nuance Dragon Medical One, Nuance CDE One, and its array of diagnostic imaging solutions such as PowerScribe One™ and PowerShare™.

“The dramatic acceleration in the digital transformation of healthcare continues as organizations deploy the power of conversational AI and deeply integrated cloud-based solutions at scale to address physician burnout, expand patient access, and improve system efficiencies and the revenue cycle,” said Mark Benjamin, CEO of Nuance. “With this strategic transaction, we’re aligning our resources to increase our market and technical leadership position in high-growth, high-impact areas that help our customers in a transformative way to improve patient care and operational performance. At the same time, we’re enabling the medical transcription and EHR Go-Live Services businesses to reach their full potential as a separate, focused company benefiting from the enhanced investment and operational experience of AHP and Aeries and technology support from Nuance.”

Michael Clark, current Senior Vice President and General Manager of Provider Solutions at Nuance, will become DeliverHealth’s CEO when the transaction closes. “This transaction will allow the EHR Go-Live Services and HIM Transcription businesses to focus on growth and expansion of value-add solutions.  The continuing strategic relationship with Nuance, the continuity of leadership, and our people’s engagement will ensure that our customers will continue to receive the outstanding service, technology, and value that they have come to expect,” said Michael Clark. “The combination of a deeper strategic focus, our partnership with Nuance, the commitment of our team, and the support provided by AHP and Aeries will create a winning formula for our customers and our employees.”

The sale demonstrates Nuance’s continuing execution to focus R&D investments in the healthcare and enterprise markets – where the company has substantial competitive advantages and opportunities for growth and value creation. In 2019, for example, Nuance sold its document imaging business to Kofax and spun-off its automotive business into Cerence, Inc., an independent, publicly-traded company.

About Assured Healthcare Partners
Assured Healthcare Partners (AHP), an extension of the Assured Investment Management platform, provides capital solutions supporting growth, consolidation, and repositioning opportunities in the healthcare services industry. AHP leverages company and sector-specific research, as well as creative structuring and capital flexibility, to unlock value for portfolio companies and investors. AHP has extensive experience investing in provider-centric businesses, which are DeliverHealth’s customer base, including post-acute care facilities, physician groups, multi-site providers, and acute care facilities. 

About Aeries Technology Group
Aeries Technology Group offers outsourcing solutions, business process management, and technological advancements to organizations seeking higher operational effectiveness, greater flexibility, and cost savings. The senior management team at Aeries has extensive experience successfully managing, developing, and optimizing healthcare service businesses.

About Nuance Communications

Nuance Communications (NASDAQ: NUAN) is a technology pioneer with market leadership in conversational AI and ambient intelligence. A full-service partner trusted by 90 percent of U.S. hospitals and 85 percent of the Fortune 100 companies worldwide, Nuance creates intuitive solutions that amplify people’s ability to help others.

Trademark reference: Nuance and the Nuance logo are registered trademarks or trademarks of Nuance Communications, Inc. or its affiliates in the United States and/or other countries. All other trademarks referenced herein are the property of their respective owners.



Media Contact:                                    


Investor Contact:

Nancy Scott                                          

Michael Maguire

Nuance Communications                      

Nuance Communications

+781.565.4130                                    

+781.565.4855


[email protected]                  


[email protected] 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/nuance-announces-sale-of-him-transcription-and-ehr-go-live-services-businesses-to-accelerate-growth-as-conversational-ai-market-leader-301176427.html

SOURCE Nuance Communications

STAG Industrial Announces Largest Rooftop Community Solar Project In The Country

PR Newswire

BOSTON, Nov. 18, 2020 /PRNewswire/ — STAG Industrial, Inc. (NYSE:STAG) today announced the groundbreaking of their first onsite solar installations in Maryland, which are owned and developed by Summit Ridge Energy (“SRE”). The three projects are part of Maryland’s community solar program and will provide low-cost renewable energy to local homes and businesses. Co-developed by Black Bear Energy and SRE, the systems have an aggregate capacity of 11.6 MW and will generate over 15 million kWh of electricity annually – the equivalent of powering nearly 1,500 homes. The installations include a 9.2 MW system on STAG’s Hampstead facility, which when completed will be the country’s largest rooftop community solar project. With the addition of these sites, STAG now hosts over 25.5 MW of solar nationally.  

“We continue to leverage our portfolio by hosting solar wherever possible, and the Maryland market provided an opportunity for us to do just that. In this case, our Hampstead facility with a large, brand new roof was an ideal fit.  It’s encouraging to know the local grid is greener thanks in part to the renewable energy generated by the solar system on our roof.” said Brian LaMont, Senior Vice President of Construction at STAG. 

“Summit Ridge Energy is thrilled to partner with STAG and Black Bear Energy on this portfolio of industrial rooftop community solar projects in Maryland. SRE continues to be the nationwide leader in financing community solar projects and is excited to start construction on what will be the country’s largest rooftop community solar project” said Nate Greenberg, Vice President of Rooftop Community Solar Development at Summit Ridge Energy.

“STAG is an industry leader in environmental stewardship and we are proud to support their efforts in onsite renewable generation. It is energizing to see our clients take action, creating value for themselves and the greater community,” commented Drew Torbin, Black Bear Energy’s Chief Executive Officer.

About STAG Industrial, Inc. 

STAG Industrial, Inc. is a real estate investment trust focused on the acquisition, ownership and operation of single-tenant, industrial properties throughout the United States. As of September 30, 2020, the Company’s portfolio consists of 462 buildings in 38 states with approximately 92.3 million rentable square feet.

For additional information, please visit the Company’s website at www.stagindustrial.com.

About Summit Ridge Energy

Summit Ridge Energy is the leading owner-operator of U.S. community solar projects. The team has been a strong force within the U.S. commercial solar market for years and was instrumental in the creation of “virtual” solar power purchase agreements and associated financing structures. Summit Ridge Energy has leveraged this experience to launch Summit Ridge Capital, a dedicated funding platform that acquires pre-operational projects within the rapidly growing community solar energy sector. Follow Summit Ridge Energy on LinkedIn and Twitter for updates, or learn more at srenergy.com.

About Black Bear Energy 

Black Bear Energy is a technology-enabled, commercial buyer’s representative specializing in onsite renewable energy and cleantech services.  In the past five years, Black Bear has helped its clients bid out over 1,000 clean technology projects in more than 20 states through its data driven process.  For more information about Black Bear Energy, visit BlackBearEnergy.com. For press inquiries, contact [email protected].

Forward-Looking Statements

This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, are generally identifiable by use of the words “believe,” “will,” “expect,” “intend,” “anticipate,” “estimate,” “should,” “project” or similar expressions. You should not rely on forward-looking statements since they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company’s control and which could materially affect actual results, performances or achievements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, the risk factors 2 discussed in the Company’s annual report on Form 10-K for the year ended December 31, 2019 as updated by the Company’s quarterly reports on Form 10-Q. Accordingly, there is no assurance that the Company’s expectations will be realized. Except as otherwise required by the federal securities laws, the Company disclaims any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/stag-industrial-announces-largest-rooftop-community-solar-project-in-the-country-301176396.html

SOURCE STAG Industrial, Inc.

Halozyme To Participate In Fireside Chat For The Piper Sandler 32nd Annual Virtual Healthcare Conference

PR Newswire

SAN DIEGO, Nov. 18, 2020 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in a fireside chat presentation for the Piper Sandler 32nd Annual Virtual Healthcare Conference.  The virtual conference will be held from December 1-3, 2020.

The pre-recorded fireside chat will be available online Wednesday, November 25 in the investor relations section of the company’s website at https://www.halozyme.com/investors/events-and-webcast/

About Halozyme

Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients’ lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme’s commercially-validated solution has positively impacted more than 400,000 patient lives via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme’s proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company’s partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

Contact:

Al Kildani

Vice President, Investor Relations and Corporate Communications
858-704-8122
[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/halozyme-to-participate-in-fireside-chat-for-the-piper-sandler-32nd-annual-virtual-healthcare-conference-301176413.html

SOURCE Halozyme Therapeutics, Inc.

Five Below, Inc. Announces Third Quarter Fiscal 2020 Earnings Release and Conference Call Date

PHILADELPHIA, PA, Nov. 18, 2020 (GLOBE NEWSWIRE) — Five Below, Inc. (NASDAQ:FIVE), the trend-right, high-quality extreme-value retailer for tweens, teens and beyond, today announced that its financial results for the third quarter of 2020 will be released after market close on Wednesday, December 2, 2020. The company will host a conference call at 4:30 p.m. Eastern Time to discuss the financial results.

Investors and analysts interested in participating in the call are invited to dial 412-902-6753 approximately 10 minutes prior to the start of the call. A live audio webcast of the conference call will be available online at investor.fivebelow.com.

A taped replay of the conference call will be available within two hours of the conclusion of the call and can be accessed online or by dialing 412-317-0088 and entering the access code 10149151. The replay will be available for approximately two weeks after the call.

Forward-Looking Statements:

This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which reflect management’s current views and estimates regarding the Company’s industry, business strategy, goals and expectations concerning its market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating information. Investors can identify these statements by the fact that they use words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future” and similar terms and phrases. The Company cannot assure investors that future developments affecting the Company will be those that it has anticipated. Actual results may differ materially from these expectations due to risks and uncertainties associated with the COVID-19 pandemic (including governmental restrictions and requirements, store closures and effects on customer demand or on our supply chain, our ability to keep our distribution centers and e-commerce fulfillment operational, our ability to effectively operate and remain open in some or all of our stores, and to open new stores and remodels), risks related to the Company’s strategy and expansion plans, risks related to the inability to successfully implement our online retail operations, including cyber security risks, risks related to our ability to select, obtain, distribute and market merchandise profitably, risks related to our reliance on merchandise manufactured outside of the United States, risks related to any legal proceedings that we may become subject to, the availability of suitable new store locations and the dependence on the volume of traffic to our stores, risks related to the Company’s continued retention of its executive officers, senior management and other key personnel, risks related to changes in consumer preferences and economic conditions, risks related to increased operating costs, including wage rates, risks related to extreme weather, pandemic outbreaks (in addition to COVID-19), global political events, war, terrorism or civil unrest (including any resulting store closures, damage, or loss of inventory), risks related to leasing, owning or building distribution centers, risks related to our ability to successfully manage inventory balance and inventory shrinkage, quality or safety concerns about the Company’s merchandise, increased competition from other retailers including online retailers, risks related to the seasonality of our business, risks related to our ability to protect our brand name and other intellectual property, risks related to customers’ payment methods, risks related to domestic and foreign trade restrictions including duties and tariffs affecting our domestic and foreign suppliers and increasing our costs, including, among others, the direct and indirect impact of recent and potential tariffs imposed and proposed by the United States on foreign imports, risks associated with the restrictions imposed by our indebtedness on our current and future operations, the impact of changes in tax legislation and accounting standards and risks associated with leasing substantial amounts of space. For further details and a discussion of these risks and uncertainties, see the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. If one or more of these risks or uncertainties materialize, or if any of the Company’s assumptions prove incorrect, the Company’s actual results may vary in material respects from those projected in these forward-looking statements. Any forward-looking statement made by the Company in this news release speaks only as of the date on which the Company makes it. Factors or events that could cause the Company’s actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

About
Five Below
:

Five Below is a leading high-growth value retailer offering trend-right, high-quality products loved by tweens, teens and beyond. We know life is way better when you’re free to “let go & have fun” in an amazing experience filled with unlimited possibilities. With most items priced $1-$5, and some extreme value items priced up to just $10, we make it easy to say YES! to the newest, coolest stuff across 8 awesome Five Below worlds: Style, Room, Play, Create, Party, Candy, New & Now and Ten Below Tech. Founded in 2002 and headquartered in Philadelphia, Pennsylvania, Five Below today has over 1,000 stores in 38 states. For more information, please visit fivebelow.com and a store!

Investor Contact:

Five Below, Inc.
Christiane Pelz
215-207-2658
[email protected]



Aquestive Therapeutics Completes FDA Type A Meeting on Libervant

  • FDA confirms issues identified in FDA Complete Response Letter (CRL) of September 25, 2020 may be addressed by utilizing modeling and simulations for an updated dosing regimen
  • FDA recommends and Aquestive agrees to a follow-up FDA meeting prior to resubmission

WARREN, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today the completion of a Type A meeting with the U.S. Food and Drug Administration (FDA) confirming a pathway for resubmission for approval of the Company’s drug candidate Libervant™ (diazepam) Buccal Film for management of seizure clusters.

In preliminary comments provided by the FDA prior to the Type A meeting and again at the Type A meeting held on November 12, 2020, the FDA confirmed that the issues identified in the CRL may be addressed by utilizing modeling and simulations based upon the information provided by Aquestive in its FDA meeting package submitted in October 2020. The FDA requested in its preliminary comments that Aquestive confirm that Libervant is linear across the potential dosage levels. Aquestive believes that this information is available based on previously conducted studies and will include this information in its upcoming resubmission of the New Drug Application (NDA) for Libervant. The FDA also recommended a follow-up meeting to review the final modeling and simulations, as well as the totality of safety information, prior to resubmission. Aquestive plans on scheduling this follow-up meeting with the FDA prior to resubmission.   

Based on the FDA’s preliminary comments and the discussion with the FDA during the Type A meeting, Aquestive continues to believe that no additional clinical studies will be required for the resubmission of the NDA for Libervant. Aquestive will work to prepare the analysis requested and schedule the follow-up meeting with the FDA as soon as is practical. The Company expects to resubmit the NDA for Libervant as soon as possible after the follow-up meeting, which has yet to be scheduled.   

“We are pleased with our recent interaction with the FDA,” said Keith J. Kendall, President and Chief Executive Officer of Aquestive. “The FDA has exhibited a collaborative approach to reaching a successful path for resubmission of our NDA for Libervant and we look forward to meeting with the Agency and resubmitting our NDA as quickly as possible,” concluded Mr. Kendall.

About Libervant
Libervant™ is a buccally, or inside of the cheek, administered soluble film formulation of diazepam, a benzodiazepine intended for rapid treatment of acute uncontrolled seizures in selected, refractory patients with epilepsy on stable regimens of AEDs who require intermittent use of diazepam to control bouts of increased seizure activity. Aquestive is developing Libervant as an alternative to Diastat (diazepam rectal gel), the current standard of care rescue therapy for patients with refractory epilepsy which, as a rectal gel, is invasive, inconvenient, and difficult to administer. As a result, a large portion of the patient population does not receive adequate treatment or foregoes treatment altogether. The Company believes that Libervant will enable a larger share of these patients to receive more appropriate treatment by providing consistent therapeutic dosing in a non-invasive and innovative treatment form for epileptic seizures.

About Aquestive Therapeutics

Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan, has a commercial proprietary product pipeline focused on the treatment of diseases of the central nervous system, or CNS, and other unmet needs, and is developing orally administered complex molecules to provide alternatives to invasively administered standard of care therapies. The Company also collaborates with other pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven capabilities for drug development and commercialization.

Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the FDA’s confirmation that modeling and simulations are a potential path forward to approval; the Company’s belief that the additional information requested by the FDA is available based on previously conducted studies and that no additional clinical studies will be required for resubmission of the New Drug Application (NDA) for Libervant; the timing of the NDA resubmission to the FDA; ability to address the concerns identified in the FDA’s Complete Response Letter dated September 25, 2020 regarding the NDA for Libervant and obtain FDA approval of Libervant for U.S. market access; therapeutic benefits of Libervant; and other statements that are not historical facts. These forward-looking statements are also subject to the uncertain impact of the COVID-19 global pandemic on our business including with respect to our clinical trials including site initiation, patient enrollment and timing and adequacy of clinical trials; on regulatory submissions and regulatory reviews and approvals of our product candidates; pharmaceutical ingredient and other raw materials supply chain, manufacture, and distribution; sale of and demand for our products; our liquidity and availability of capital resources; customer demand for our products and services; customers’ ability to pay for goods and services; and ongoing availability of an appropriate labor force and skilled professionals. Given these uncertainties, the Company is unable to provide assurance that operations can be maintained as planned prior to the COVID-19 pandemic. These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company’s development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials and plans; risk of delays in FDA approval of Libervant and our other drug candidates or failure to receive approval; risk of our ability to demonstrate to the FDA “clinical superiority” within the meaning of the FDA regulations of our drug candidate Libervant relative to FDA-approved diazepam rectal gel and nasal spray products including by establishing a major contribution to patient care within the meaning of FDA regulations relative to the approved products as well as risks related to other potential pathways or positions which are or may in the future be advanced to the FDA to overcome the seven year orphan drug exclusivity granted by the FDA for the approved nasal spray product of a competitor in the U.S. and there can be no assurance that we will be successful; risk that a competitor obtains other FDA marketing exclusivity that blocks U.S. market access for Libervant; risk inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations); risks for consummating the monetization transaction for KYNMOBI™ and other risks and uncertainties concerning the royalty and other revenue stream of KYNMOBI, achievement of royalty targets worldwide or in any jurisdiction and certain other commercial targets required for contingent payments under the monetization transaction, and of sufficiency of net proceeds of the monetization transaction after satisfaction of and compliance with 12.5% Senior Notes obligations, as applicable, and for funding the Company’s operations; risk of development of our sales and marketing capabilities; risk of legal costs associated with and the outcome of our patent litigation challenging third party at risk generic sale of our proprietary products; risk of sufficient capital and cash resources, including access to available debt and equity financing and revenues from operations, to satisfy all of our short-term and longer term cash requirements and other cash needs, at the times and in the amounts needed; risk of failure to satisfy all financial and other debt covenants and of any default; risk related to government claims against Indivior for which we license, manufacture and sell Suboxone® and which accounts for the substantial part of our current operating revenues; risk associated with Indivior’s cessation of production of its authorized generic buprenorphine naloxone film product, including the impact from loss of orders for the authorized generic product and risk of eroding market share for Suboxone and risk of sunsetting product; risks related to the outsourcing of certain marketing and other operational and staff functions to third parties; risk of the rate and degree of market acceptance of our product and product candidates; the success of any competing products, including generics; risk of the size and growth of our product markets; risks of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities; risks associated with intellectual property rights and infringement claims relating to the Company’s products; risk of unexpected patent developments; the impact of existing and future legislation and regulatory provisions on product exclusivity; legislation or regulatory actions affecting pharmaceutical product pricing, reimbursement or access; claims and risks that may arise regarding the safety or efficacy of the Company’s products and product candidates; risk of loss of significant customers; risks related to legal proceedings, including patent infringement, investigative and antitrust litigation matters; changes in government laws and regulations; risk of product recalls and withdrawals; uncertainties related to general economic, political, business, industry, regulatory and market conditions and other unusual items; and other uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in our Annual Report on Form 10-K, in our Quarterly Reports on Form 10-Q, and in our Current Reports on Form 8-K filed with the Securities Exchange Commission. Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law.

PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All other registered trademarks referenced herein are the property of their respective owners.

Investor Inquiries:
Westwicke, an ICR Company
Stephanie Carrington
[email protected]
646-277-1282